49. The compound of claim 34, wherein R^4 is a substituted or unsubstituted non-aromatic heterocyclyl.

50. The compound of claim 49, wherein R^4 is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, piperidinonyl or 1,4-dioxaspiro[4.5]decanyl.

51. The compound of claim 45, wherein R^3 is a cycloalkyl, optionally substituted with one or more halogen, $-CF_3$, $-(C_{1-4}$ alkyl), $-NR_2$, $-(C_{0-3}$ alkyl)OR, $-(C_{0-3}$ alkyl)OR", -NRC(O)R', -C(O)R', $-C(O)NR_2$, -C(O)OR', or $-NRS(O)_2R'$, wherein each R is independently H, or C_{1-4} alkyl, wherein the alkyl is optionally fluorinated, each R' is independently C_{1-4} alkyl, wherein the alkyl is optionally fluorinated, and each R" is independently a C_{1-6} cycloalkyl, wherein the cycloalkyl is optionally fluorinated.

52. The compound of claim 34, wherein the compound at a concentration of 10 μM inhibits JNK1 by at least about 50%.

53. The compound of claim 34, wherein the compound is selected from Table 3.

54. A pharmaceutical composition comprising an effective amount of a compound of claim 1, 32, 33, 34, or 53, or a pharmaceutically acceptable salt, tautomer, isotopologue, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

55. Use of a compound of claim 1, 32, 33, 34, or 53, or a pharmaceutically acceptable salt, tautomer, isotopologue, stereoisomer, or prodrug thereof for use in the manufacture of a medicament for ~~A method of~~ inhibiting a kinase in a cell expressing said kinase~~, comprising contacting said cell with an effective amount of a compound of claim 1, 32, 33, 34, or 53, or a pharmaceutically acceptable salt, tautomer, isotopologue, stereoisomer, or prodrug thereof~~.

56. The ~~method~~ use of claim 55, wherein the kinase is one or more of JNK1 or JNK2.

57. Use of a compound of claim 1, 32, 33, 34, or 53 in the manufacture of a medicament for ~~A method for the~~ treatment or prevention of liver fibrotic disorders, or diabetes or metabolic syndrome leading to liver fibrotic disorders~~, the methods comprising~~

~~administering to a subject in need thereof an effective amount of a compound of claim 1, 32, 33, 34, or 53~~.

58. The ~~method~~ use of claim 57, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury.

59. The ~~method~~ use of claim 57, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, hepatitis, or cirrhosis.